About Anika Therapeutics (NASDAQ:ANIK)
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company's therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company's ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000
Debt
Debt-to-Equity RatioN/A
Current Ratio15.79%
Quick Ratio14.10%
Price-To-Earnings
Trailing P/E Ratio23.03
Forward P/E Ratio28.75
P/E Growth2.92
Sales & Book Value
Annual Sales$113.42 million
Price / Sales5.87
Cash Flow$2.2667 per share
Price / Cash19.91
Book Value$17.97 per share
Price / Book2.51
Profitability
EPS (Most Recent Fiscal Year)$1.96
Net Income$31.81 million
Net Margins28.05%
Return on Equity11.91%
Return on Assets11.05%
Miscellaneous
Employees123
Outstanding Shares14,740,000
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) released its earnings results on Wednesday, February, 21st. The biotechnology company reported $0.38 EPS for the quarter, missing analysts' consensus estimates of $0.41 by $0.03. The biotechnology company had revenue of $29.39 million for the quarter, compared to analysts' expectations of $29.85 million. Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The firm's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.54 EPS. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What price target have analysts set for ANIK?
3 brokerages have issued twelve-month price objectives for Anika Therapeutics' shares. Their forecasts range from $57.00 to $68.00. On average, they expect Anika Therapeutics' share price to reach $62.50 in the next year. View Analyst Ratings for Anika Therapeutics.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG), CryoLife (CRY), LeMaitre Vascular (LMAT), Cardiovascular Systems (CSII), AtriCure (ATRC), AngioDynamics (ANGO), Cerus (CERS), Tactile Systems Technology (TCMD), SurModics (SRDX), Inovio Pharmaceuticals (INO) and Accuray (ARAY).
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Joseph G. Darling, President, Chief Executive Officer, Director (Age 59)
- Sylvia Cheung, Chief Financial Officer, Treasurer, Secretary (Age 42)
- Edward Ahn Ph.D., Chief Technology and Strategy Officer (Age 45)
- Richard Hague, Chief Commercial Officer (Age 57)
- Joseph Lyon Bower Ph.D., Lead Independent Director (Age 79)
- Raymond J. Land, Independent Director (Age 72)
- Glenn R. Larsen Ph.D., Independent Director (Age 62)
- Jeffrey S. Thompson, Independent Director (Age 51)
- Steven E. Wheeler, Independent Director (Age 70)
Has Anika Therapeutics been receiving favorable news coverage?
News stories about ANIK stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Anika Therapeutics earned a media sentiment score of 0.11 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
SHERWOOD CHARLES H
(5.15%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Jeffery S Thompson, Joseph I Bower and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $45.13.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $676.95 million and generates $113.42 million in revenue each year. The biotechnology company earns $31.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Anika Therapeutics employs 123 workers across the globe.
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Anika Therapeutics (NASDAQ:ANIK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Anika Therapeutics in the last 12 months. Their average twelve-month price target is $62.50, suggesting that the stock has a possible upside of 38.49%. The high price target for ANIK is $68.00 and the low price target for ANIK is $57.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 2.67 | 2.67 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $62.50 | $62.50 | $57.00 | N/A |
| Price Target Upside: | 38.49% upside | 8.30% upside | 6.76% upside | N/A |
Anika Therapeutics (NASDAQ:ANIK) Consensus Price Target History
Anika Therapeutics (NASDAQ:ANIK) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Anika Therapeutics (NASDAQ:ANIK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Anika Therapeutics (NASDAQ ANIK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.57%
Institutional Ownership Percentage: 84.10%
Anika Therapeutics (NASDAQ ANIK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/30/2017 | Richard Hague | Insider | Sell | 5,250 | $54.48 | $286,020.00 | |  |
| 10/23/2017 | Charles H Sherwood | CEO | Sell | 22,228 | $60.06 | $1,335,013.68 | 158,297 | |
| 10/20/2017 | Charles H Sherwood | CEO | Sell | 5,991 | $60.04 | $359,699.64 | 158,297 | |
| 10/16/2017 | Charles H Sherwood | CEO | Sell | 3,293 | $60.04 | $197,711.72 | | |
| 10/13/2017 | Charles H Sherwood | CEO | Sell | 7,124 | $60.08 | $428,009.92 | | |
| 7/27/2017 | Charles H Sherwood | CEO | Sell | 63,799 | $50.79 | $3,240,351.21 | 174,705 | |
| 7/5/2017 | Charles H Sherwood | CEO | Sell | 14,201 | $50.03 | $710,476.03 | 246,740 | |
| 5/22/2017 | Jeffery S Thompson | Director | Sell | 10,725 | $47.39 | $508,257.75 | 15,845 | |
| 11/9/2016 | Joseph I Bower | Director | Sell | 540 | $43.39 | $23,430.60 | 38,513 | |
| 2/25/2016 | Raymond J Land | Director | Sell | 2,695 | $43.62 | $117,555.90 | 14,165 | |
| 2/27/2015 | Raymond J Land | Director | Sell | 4,621 | $39.49 | $182,483.29 | | |
| 5/1/2014 | Charles H Sherwood | CEO | Sell | 83,780 | $44.32 | $3,713,129.60 | | |
| 2/28/2014 | Charles H Sherwood | CEO | Sell | 200,000 | $41.70 | $8,340,000.00 | | |
| 8/22/2013 | John C Moran | Director | Sell | 5,000 | $24.35 | $121,750.00 | | |
| 8/8/2013 | Steve E Wheeler | Director | Sell | 26,984 | $23.61 | $637,092.24 | | |
| 8/7/2013 | Steve E Wheeler | Director | Sell | 11,016 | $27.01 | $297,542.16 | | |
| 8/6/2013 | Farmaceutici S.P.A. Fidia | Major Shareholder | Sell | 1,270,000 | $24.52 | $31,140,400.00 | | |
| 7/15/2013 | Charles H Sherwood | CEO | Sell | 75,000 | $20.11 | $1,508,250.00 | | |
| 7/9/2013 | Charles H Sherwood | CEO | Sell | 49,185 | $18.06 | $888,281.10 | | |
| 7/5/2013 | Charles H Sherwood | CEO | Sell | 34,662 | $18.01 | $624,262.62 | | |
| 6/19/2013 | Charles H Sherwood | CEO | Sell | 1,847 | $18.00 | $33,246.00 | | |
(Data available from 1/1/2013 forward)
Anika Therapeutics (NASDAQ ANIK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Anika Therapeutics (ANIK) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - April 20 at 11:54 AM |
 | Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
finance.yahoo.com - April 18 at 5:32 PM |
| Anika Therapeutics Inc (ANIK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 11:20 PM |
| Anika Therapeutics (ANIK) Downgraded by ValuEngine
www.americanbankingnews.com - April 12 at 10:19 PM |
| Anika Therapeutics (ANIK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 12 at 7:25 PM |
| Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
finance.yahoo.com - April 6 at 8:46 AM |
| Brokerages Anticipate Anika Therapeutics Inc (ANIK) to Post $0.25 Earnings Per Share
www.americanbankingnews.com - March 30 at 3:24 AM |
| With A -2.25% Earnings Drop, Is Anika Therapeutics Inc’s (FRA:AKP) A Concern?
finance.yahoo.com - March 29 at 8:44 AM |
| Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 26 at 1:32 AM |
| Edited Transcript of ANIK earnings conference call or presentation 22-Feb-18 2:00pm GMT
finance.yahoo.com - March 22 at 5:24 PM |
| Brokerages Set $68.00 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 20 at 1:18 AM |
 | Director's Letter Micro Cap Summary - March 2018
seekingalpha.com - March 15 at 5:53 PM |
| Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
finance.yahoo.com - March 14 at 8:58 AM |
| Critical Review: Anika Therapeutics (ANIK) and Onconova Therapeutics (ONTX)
www.americanbankingnews.com - March 10 at 12:17 PM |
 | Joseph Darling Named CEO and Director of Anika Therapeutics - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM |
| Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting - GlobeNewswire (press release)
globenewswire.com - March 6 at 8:32 AM |
| Analysts Set $68.00 Price Target for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - March 5 at 5:14 AM |
| Anika Therapeutics Inc (ANIK) Holdings Lifted by Bbva Compass Bancshares Inc.
www.americanbankingnews.com - March 1 at 4:56 AM |
| First Analysis Comments on Anika Therapeutics Inc's FY2019 Earnings (ANIK)
www.americanbankingnews.com - February 28 at 3:18 PM |
| First Analysis Brokers Decrease Earnings Estimates for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 27 at 8:38 AM |
| New Strong Sell Stocks for February 27th
finance.yahoo.com - February 27 at 8:37 AM |
| Anika Therapeutics Inc (ANIK) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 8:37 AM |
| Anika Therapeutics (ANIK) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 26 at 5:24 PM |
| Equities Analysts Issue Forecasts for Anika Therapeutics Inc's Q1 2018 Earnings (ANIK)
www.americanbankingnews.com - February 26 at 3:18 AM |
| Anika Therapeutics (ANIK) Lowered to Hold at BidaskClub
www.americanbankingnews.com - February 24 at 3:52 PM |
| Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 24 at 8:30 AM |
 | Anika Therapeutics (NASDAQ:ANIK) Shares Stunted By Increased ... - Benzinga
www.benzinga.com - February 24 at 8:30 AM |
| Kamada (KMDA) and Anika Therapeutics (ANIK) Critical Survey
www.americanbankingnews.com - February 24 at 1:06 AM |
| Anika Therapeutics Shares Stunted By Increased Investment, Barrington Says In Downgrade
finance.yahoo.com - February 23 at 5:42 PM |
| Anika Therapeutics (ANIK) Rating Lowered to Market Perform at Barrington Research
www.americanbankingnews.com - February 23 at 4:28 PM |
| Anika Therapeutics Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 22 at 5:27 PM |
| Anika Therapeutics (ANIK) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - February 22 at 3:26 PM |
| Anika Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - February 21 at 5:17 PM |
| When Should You Buy Anika Therapeutics Inc (NASDAQ:ANIK)?
finance.yahoo.com - February 21 at 5:17 PM |
| Zacks: Anika Therapeutics Inc (ANIK) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 18 at 3:14 AM |
| Anika Therapeutics (ANIK) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 14 at 4:32 AM |
| Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
finance.yahoo.com - February 8 at 8:21 AM |
| Anika Therapeutics (ANIK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 6 at 3:12 AM |
| Analysts Set $62.50 Target Price for Anika Therapeutics Inc (ANIK)
www.americanbankingnews.com - February 3 at 3:26 AM |
| Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
finance.yahoo.com - February 2 at 9:46 AM |
| First Analysis Upgrades Anika Therapeutics (ANIK) to "Overweight"
www.americanbankingnews.com - January 28 at 6:36 PM |
| Anika Therapeutics (ANIK) Lifted to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 10:16 AM |
| Sidoti Initiates Coverage on Anika Therapeutics (ANIK)
www.americanbankingnews.com - January 26 at 4:54 PM |
| First Analysis Weighs in on Anika Therapeutics Inc's Q4 2017 Earnings (ANIK)
www.americanbankingnews.com - January 26 at 6:46 AM |
| Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
finance.yahoo.com - January 25 at 9:46 AM |
| First Analysis Weighs in on Anika Therapeutics Inc's FY2017 Earnings (ANIK)
www.americanbankingnews.com - January 25 at 7:58 AM |
| Recent Analysis Shows Darling Ingredients, Principal Financial Group, UGI, Cass Information, WD-40, and Anika Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - January 22 at 9:22 AM |
| Analysts Set $57.00 Price Target for Anika Therapeutics Inc. (ANIK)
www.americanbankingnews.com - January 19 at 3:58 AM |
| Anika Therapeutics (ANIK) and 3SBio (SSRX) Head to Head Analysis
www.americanbankingnews.com - January 6 at 1:36 PM |
| Anika Therapeutics Inc. (ANIK) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 4 at 2:00 AM |
Anika Therapeutics (NASDAQ:ANIK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Anika Therapeutics (NASDAQ:ANIK) Income Statement, Balance Sheet and Cash Flow Statement
Anika Therapeutics (NASDAQ ANIK) Stock Chart for Saturday, April, 21, 2018
Loading chart…
